問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

賴柏如
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴柏如

Chung Shan Medical University Hospital

Division of Dermatology

List

26Cases

2020-05-20 - 2023-09-11

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Suspended4Sites

2019-06-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-07-31 - 2026-05-27

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-05-15 - 2030-04-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-04-15 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-09-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-02-01 - 2021-12-31

Phase III

A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable

  • Condition/Disease

    Neurodermatitis

  • Test Drug

    Dupilumab Dupilumab

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2018-12-13 - 2020-12-09

Phase III

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    ABT-494 (Upadacitinib)

Participate Sites
4Sites

Terminated4Sites

2021-10-01 - 2024-03-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-07-10 - 2020-02-12

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    REGN3500 and REGN668 (Dupilumab)

Participate Sites
4Sites

Terminated4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB